Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2025 Earnings Call Transcript
Operator: Good morning -- good afternoon, ladies and gentlemen. My name is Sherry, and I will be your conference call operator today.
Puma Biotechnology Inc. (PBYI)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 2,123,813 | $12,636,687 | -2% | 0.02% |
| 2. | AQR Capital Management Cliff Asness | 666,605 | $3,966,300 | +411% | 0% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 547,853 | $3,259,725 | +18% | 0% |
| 4. | D E Shaw D. E. Shaw | 378,296 | $2,250,861 | -25% | 0% |
| 5. | Citadel Investment Group Ken Griffin | 162,670 | $967,887 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.49 | 28 | $2,309.72 | 30 | 2014-04-11 | Filing | |
| $87.35 | 2 | $174.70 | 2 | 2014-04-09 | Filing | |
| $38.92 | 22,549 | $877,607.08 | 5,686,668 | 2013-11-08 | Filing | |
| $39.60 | 280,700 | $11,115,720.00 | 5,664,119 | 2013-11-05 | Filing | |
| $40.08 | 54,200 | $2,172,336.00 | 5,383,419 | 2013-10-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.88 | 18,012 | $105,892.55 | 7,145,951 | 2026-01-07 | Filing | |
| $5.84 | 16,938 | $98,985.67 | 7,163,963 | 2026-01-06 | Filing | |
| $5.88 | 5,014 | $29,477.31 | 155,907 | 2026-01-07 | Filing | |
| $5.84 | 3,973 | $23,218.21 | 160,921 | 2026-01-06 | Filing | |
| $5.88 | 6,405 | $37,655.00 | 193,284 | 2026-01-07 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,635 | $80,282 | 0% | |
| 2. | 566 | $3,826 | 0% | |
| 3. | 422 | $2,697 | 0% |
News See All
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2025 Earnings Call Transcript
Operator: Good afternoon. My name is Julian, and I will be your conference call operator today. [Operator Instructions] as a reminder, this call is being recorded.
What Do Analysts Think About Puma Biotechnology (PBYI)?
Puma Biotechnology, Inc. (NASDAQ:PBYI) is one of the best affordable biotech stocks to invest in now. Puma Biotechnology, Inc.
12 Affordable Biotech Stocks to Invest In Now
On September 4, Mizuho healthcare strategist Jared Holz appeared on CNBC's ‘Power Lunch’ to talk about the changing sentiment in the healthcare sector, the differences in the biotech ETFs, and more...
Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT
Puma Biotechnology, Inc. (NASDAQ:PBYI) is one of the top most undervalued biotech stocks to buy now.
10 Most Undervalued Biotech Stocks to Buy Now
On July 25, Salveen Richter, Goldman Sachs' lead biotech analyst, appeared on CNBC’s ‘Squawk Box’ to talk about the state of the biotech sector and what to expect from the earnings season, among...
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2025 Earnings Call Transcript
Operator: Good afternoon. My name is Latanya, and I will be your conference call operator today. [Operator Instructions] As a reminder, this call is being recorded.
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2025 Earnings Call Transcript
Operator: Good afternoon. My name is Sherry, and I will be your conference call operator today. [Operator Instructions] As a reminder, this call is being recorded.
10 Best Short-Term Stocks To Buy Right Now
Thrilling highs, daunting lows, and the energized chase after the next big opportunity – this thoroughly defines the current stock market.
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2024 Earnings Call Transcript
Operator: Good afternoon. My name is Darrell and I will be your conference call operator today. At this time, all participants are in a listen-only mode.